Drug intelligence / Profile preview

AAV-VEGFR2

Development stage: Preclinical
Lead developer: MeiraGTx Holdings
Modality: Gene Therapies
Administration: Ophthalmic

Overview

AAV-VEGFR2 is a preclinical gene therapy candidate being developed by MeiraGTx for the treatment of wet age-related macular degeneration (AMD). The therapy utilizes an adeno-associated virus (AAV) vector to target vascular endothelial growth factor receptor 2 (VEGFR2), with the goal of inhibiting the pathological angiogenesis and vascular leakage characteristic of neovascular AMD. By delivering genetic material directly to retinal cells, AAV-VEGFR2 is designed to provide a sustained anti-angiogenic effect from a single administration, potentially reducing the treatment burden associated with frequent intravitreal injections of standard-of-care anti-VEGF agents.

Other names: MeiraGTx VEGFR2 gene therapy

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on AAV-VEGFR2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV-VEGFR2.

Explore the full profile